StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$270.56−2.64 (-0.97%)

Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%

Johnson & Johnson COVID-19 Vaccine [reported through FY2024Q4] by Year

COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide sales ($M) ($M)

QuarterlyAnnual

Johnson & Johnson COVID-19 Vaccine [reported through FY2024Q4]: $198M in FY2024, down 82.3% from a year earlier. No newer figure appears in the documents we track.

Latest, FY2024
198
Period ended Dec 29, 2024
Change on a year earlier
-82.3%
1,117 in FY2023
History
6 years
Since FY2019
Sources
4
Documents cited below

Where the FY2024 figure comes from

Source: Form 10-K (filed 2025-02-13) ↗

Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCOVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide sales ($M) ($M)Year on yearSource
FY2024Dec 29, 2024198-82.3%Form 10-K (filed 2025-02-13) ↗
FY2023Dec 31, 20231,117-48.7%Form 10-K (filed 2025-02-13) ↗
FY2022Jan 1, 20232,179-8.6%Form 10-K (filed 2025-02-13) ↗
FY2021Jan 2, 20222,385–Form 10-K (filed 2024-02-16) ↗
FY2020Jan 3, 20210–Form 10-K (filed 2023-02-16) ↗
FY2019Dec 29, 20190–Form 10-K (filed 2022-02-17) ↗

Breakdown

What makes up COVID-19 Vaccine [reported through FY2024Q4]

Cite this data

StockData. (2026). Johnson & Johnson COVID-19 Vaccine [reported through FY2024Q4] ($M), annual FY2019–FY2024 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-covid19

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.